Community-based Microalbuminuria Screening in Patients With Hypertension

Hypertension Clinical Trial

— CMSIH  

Official title:

Effectiveness of Different Antihypertensive Medications on Urine Albumin-to-Creatinine Ratio (UACR) in Community Hypertensive Patients With Microalbuminuria

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03596840
• Other study ID #: B2018-106
• Status: Not yet recruiting
• Start date: August 1, 2018
• Est. completion date: December 31, 2020

Study information

• Verified date: July 2018
• Source: Shanghai Zhongshan Hospital
• Contact: Xuejuan Jin, MS
• Phone: +86-13681973269
• Email: jin.xuejuan[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

Description:

This is a a real world registry study. All patients with hypertension in community hospitals in China will be eligible . Patient demographics, medical history, clinical characteristics, physical examination, laboratory tests (including UCAR, blood routine, urine routine, blood biochemistry, and ECG), antihypertensive drugs (including: ACEI/ ARB, thiazide diuretics, CCB, beta-blockers, alpha-blockers, and other antihypertensive drugs used in real-life clinical practice in other communities.) will be recorded. All patients are anticipated to be followed up for 12-month. Effectiveness of different antihypertensive medications on Urine Albumin-to-Creatinine Ratio (UACR) will be evaluted.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 3000
• Est. completion date: December 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with essential hypertension;

• Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g

• Age >=18

• Understand and sign informed consent

Exclusion Criteria:

• This is a real-world registry study and does not set exclusion criteria

Related Conditions & MeSH terms

• Albuminuria
• Hypertension
• Microalbuminuria

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine Albumin-to-Creatinine Ratio (UCAR)	Differences in UCAR between with ACEI/ARB and without ACEI/ARB	12 months
Secondary	Combined endpoints: re-admission, cardiovascular events, and all-cause mortality	Differences in Combined endpoints between with ACEI/ARB and without ACEI/ARB	12 months